TruScreen Group (TRU) H2 2026 earnings summary

Executive summary

• FY26 annual sales reached NZD $2.4m (or $2.43 million), representing 42% year-over-year growth, with revenue up 33% year-over-year.

• Expansion into new markets with distributor appointments in South Africa, Uzbekistan, Bangladesh, Romania, and Italy.

• Major public health programs launched, including a 260,000-woman screening initiative in Vietnam and re-entry into India.

• Landmark BMC Cancer study published, confirming high sensitivity and accuracy of the screening device.

• Significant capital raise completed in May 2026, with further funds expected from a rights issue.

Financial highlights

• FY26 sales increased 42% year-over-year to NZD $2.4m; revenue up 33% year-over-year.

• EBITDA remained flat year-over-year at -$2.2m; net loss for the year was $2.25 million, nearly flat compared to $2.24 million in the prior year.

• Net assets rose 160% year-over-year to NZD $2.6m.

• Cash and cash equivalents at year-end rose to NZD $1.5m (or $1.46 million) from $0.37 million year-over-year.

• China accounted for 61.3% of FY26 sales, with Zimbabwe at 22.4%.

Outlook and guidance

• FY27 growth driven by anticipated regulatory approvals in India and South Africa, and commercial launches in Indonesia and Uzbekistan.

• Gross margin expected to rise above FY26's 31.5% due to favorable country mix.

• National expansion planned in Vietnam and further scale-up in Uzbekistan.

• UNITAID funding decisions and new market activations expected in H2 CY2026.

• Cash flow forecasts indicate sufficient liquidity, but directors highlight material uncertainty regarding the ability to meet forecasts, casting doubt on going concern status.